AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI- 35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment
New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today presented new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti- phosphorylated-Tau (pTau) vaccine candidate being developed in partnership with Janssen Pharmaceuticals, Inc., at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, which is being held in Boston, Massachusetts from November 9-12, 2021.